NASDAQ-listed Gelteq secures $3.5 million debt facility to fund clinical trials and product commercialization efforts.
Gelteq Limited (NASDAQ: GELS) announced it has secured up to $3.5 million in debt financing to accelerate commercialization and clinical trial programs. The company will receive $1 million immediately, with an additional $2.5 million available pending shareholder approval in June.
Proceeds will support regulatory pathways for pharmaceutical products and the rollout of nutraceutical offerings. The financing includes a six-month repayment holiday, providing near-term liquidity without immediate cash outflows.
The funding aims to bolster revenue growth as Gelteq expands its clinical trial pipeline and commercial operations.